Q1 EPS Estimates for HRTX Decreased by Northland Securities

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Equities researchers at Northland Securities dropped their Q1 2026 earnings per share estimates for Heron Therapeutics in a research note issued on Thursday, March 26th. Northland Securities analyst C. Byrnes now forecasts that the biotechnology company will post earnings per share of ($0.02) for the quarter, down from their previous estimate of ($0.01). The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The company had revenue of $40.59 million for the quarter, compared to analyst estimates of $39.53 million.

HRTX has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Heron Therapeutics in a report on Friday, January 9th. Finally, Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 27th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Stock Up 7.3%

NASDAQ HRTX opened at $0.80 on Monday. The business’s fifty day simple moving average is $1.11 and its 200-day simple moving average is $1.20. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. The firm has a market cap of $150.85 million, a PE ratio of -6.15 and a beta of 1.26. Heron Therapeutics has a 52 week low of $0.74 and a 52 week high of $2.61.

Hedge Funds Weigh In On Heron Therapeutics

A number of hedge funds have recently modified their holdings of HRTX. SG Americas Securities LLC increased its position in shares of Heron Therapeutics by 39.1% during the 4th quarter. SG Americas Securities LLC now owns 24,377 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 6,858 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Heron Therapeutics by 5.1% in the second quarter. The Manufacturers Life Insurance Company now owns 241,048 shares of the biotechnology company’s stock valued at $499,000 after buying an additional 11,716 shares during the last quarter. B. Riley Wealth Advisors Inc. purchased a new position in Heron Therapeutics during the second quarter worth about $26,000. Police & Firemen s Retirement System of New Jersey boosted its stake in Heron Therapeutics by 53.4% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 38,352 shares of the biotechnology company’s stock worth $79,000 after buying an additional 13,352 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Heron Therapeutics by 19.3% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,756 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 13,544 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.